baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

Genmab A/S/ DK0010272202 /

2024-08-28 9:23:45 PM	Chg. -0.3200	Volume	Bid-	Ask-	Market Capitalization	Dividend Y.	P/E Ratio
271.7160USD	-0.12%	101 Turnover: 27,608.1620	-Bid Size: -	-Ask Size: -	18.5 bill.USD	-	-

GlobeNewswire 08-19 TEPKINLY® (epcoritamab) Receives Second European Commission Approval for the Treatment of Adults wit...

GlobeNewswire 08-16 Pfizer and BioNTech Provide Update on mRNA-based Combination Vaccine Program Against Influenza and C...

GlobeNewswire 08-13 Bolt Biotherapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire 08-08 Genmab Announces Financial Results for the First Half of 2024

GlobeNewswire 08-08 Genmab Updates 2024 Financial Guidance

GlobeNewswire 08-05 Avalyn Appoints Erin Lavelle, Seasoned Biopharma Finance Executive, to its Board of Directors

GlobeNewswire 08-05 BioNTech Announces Second Quarter 2024 Financial Results and Corporate Update

GlobeNewswire 08-05 Genmab Takes Full Control of Acasunlimab Development Program

GlobeNewswire 07-30 BioNTech Announces Positive Topline Phase 2 Results for mRNA Immunotherapy Candidate BNT111 in Patie...

GlobeNewswire 07-22 BioNTech to Report Second Quarter 2024 Financial Results and Corporate Update on August 5, 2024

GlobeNewswire 06-28 Epcoritamab (TEPKINLY®) Receives Positive CHMP Opinion for the Treatment of Adults with Relapsed/ Re...

GlobeNewswire 06-27 Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron JN.1-adapted COVID-19 Vaccine in the E...

GlobeNewswire 06-24 BioNTech and DualityBio Receive FDA Fast Track Designation for Antibody-Drug Conjugate Candidate BNT...

GlobeNewswire 06-01 Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates M...

GlobeNewswire 05-29 BioNTech and CEPI Expand Partnership to Strengthen Africa’s mRNA Vaccine Ecosystem

GlobeNewswire 05-21 Genmab Completes Acquisition of ProfoundBio

GlobeNewswire 05-21 BioNTech to Present Clinical Data Updates for Next-Generation Immunotherapy Candidates at the ASCO A...

GlobeNewswire 05-17 BioNTech SE Shareholders Approve All Agenda Items at the Annual General Meeting 2024

GlobeNewswire 05-14 Bolt Biotherapeutics Reports First Quarter 2024 Results, Announces Strategic Pipeline Prioritization...

GlobeNewswire 05-14 Immatics Announces First Quarter 2024 Financial Results and Business Update

GlobeNewswire 05-06 BioNTech Announces First Quarter 2024 Financial Results and Corporate Update

GlobeNewswire 05-02 Genmab Announces Financial Results for the First Quarter of 2024

GlobeNewswire 04-30 TIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervica...

GlobeNewswire 04-22 BioNTech to Report First Quarter 2024 Financial Results and Corporate Update on May 6, 2024

GlobeNewswire 04-07 Three-year Phase 1 Follow-Up Data for mRNA-based Individualized Immunotherapy Candidate Show Persis...

Genmab A/S/ DK0010272202 /

If you wish to receive reply to your feedback, please provide your email address.